Welcome to ProBioGen

ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider. We perform cell line engineering, process development, and GMP manufacturing of biopharmaceuticals for clients in biotech and pharma. We offer proprietary innovative technologies for optimized biopharmaceutical manufacturing and analysis. ProBioGen also provides process development services and manufacturing technologies for viral vaccines.

With almost 25 years of experience in mammalian cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain end-to-end.
 

Our History

1994 – ProBioGen founded as a diagnostic company

2000 – Strategic shift towards therapeutic protein contract development and GMP manufacturing

2001 – Cell line development platform established

2002 – Manufacturing authorization granted, using single-use bioreactors right from the beginning

2003 – First client designer cell line developed

2005 – More than 15 patent families granted

2008 – First commercial license for AGE1.CR duck cell line

2010 – Strategic Investor: Minapharm Pharmaceuticals

2011 – First commercial license given for GlymaxX® ADCC enhancement technology

2013 – First product produced with ProBioGen CHO cell line entered the market

2016 – First product produced on AGE1.CR® duck cell line entered the market

2017 – More than 400 stable cell lines developed

 

One-Stop-Shop

 

Global Customer Base

We are the partner of choice for biopharmaceutical companies relying on high quality cell line development and manufacturing capabilities. Our partners value our outstanding service quality, combined with variable project and deal structures, our quick responses and our flexibility.

Our clients benefit from custom-tailored projects designed to minimize development risks and ensure a successful outcome. Our experienced and flexible team of scientists, engineers, and technicians draws its motivation from the success of our clients’ projects. We are a reliable and agile partner in developing our clients’ products to the benefit of patients worldwide.

A new building is currently refurbished to house 1000L single-use bioreactor lines to keep up with the ever-increasing demand from our clients, starting operation in 2018.

Management

Since its foundation in 1994, ProBioGen has evolved from a research-based company into a fully grown, commercially successful biopharmaceutical organization. Apart from its cutting-edge, market-driven technologies, its success also lies in the dedication of its staff and, above all, the experience of its management team that brings a wealth of knowledge in the different areas of our day-to-day operations and an in-depth understanding of the trends and needs of the industry.

Dr. Wieland W. Wolf, Chief Executive Officer
Dr. Wieland W. Wolf, Chief Executive Officer

CEO of ProBioGen since June 14, 2010. Dr Wieland W. Wolf regards the positioning of ProBioGen as a leading, science-driven contract partner for biopharmaceutical development and production within a network of strategic alliances and co-operations as his pre-eminent task. He particularly aims to further deepen/broaden ProBioGen’s excellent scientific expertise and its unique technological know-how, to the benefit of ProBioGen's customers.

Looking back over three decades of biopharmaceutical experience, Wieland W. Wolf has held several leading positions in the biopharmaceutical industry. A biologist by training, he was involved in pioneering product registrations at Bioferon GmbH, headed a production unit for API and parenteral dosage forms in the same company. He was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organization (CMO). He is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (IGB, Stuttgart, Germany).

Dr. Volker Sandig, Chief Scientific Officer
Dr. Volker Sandig, Chief Scientific Officer

Volker Sandig initiated ProBioGen’s cell line development program in 2000 resulting in the unique Cell Line platform CHORight and development of the CHO-Freedom Kit with LTC (now Thermo-Fisher). He directs expansion of the company's technology portfolio, manages its broad intellectual property base and is inventor of multiple technologies including GlymaxX. In addition, his work aims at modernizing manufacture of viral vaccines and gene therapy vectors through customized design of new cell lines and innovative processes to support a wide range of human and animal viruses. Prior to joining ProBioGen, he lead a research group at Merck Research Laboratories, USA, focusing on the development of manufacturing systems for gutless adenoviruses and vectored vaccines. Volker Sandig holds a medical degree and received his doctorate in Molecular Biology from the Humboldt University, Berlin.

Dr. Gabriele Schneider, Chief Business Officer
Dr. Gabriele Schneider, Chief Business Officer

Chief Business Officer since November 2017 following 10 years as Vice President Business Development. Gabriele is responsible for commercial and business strategy and manages all activities pertaining to business development. She has an established track record of building strong and lasting relationships with clients and partners worldwide. She joined the biotech industry in 2000 as Project Manager at Kelman GmbH and was consulting small biotech companies before joining ProBioGen in 2003. Gabriele holds a master’s degree in political science from Johann Wolfgang Goethe University Frankfurt and a doctorate from Humboldt University Berlin, Germany.

Dr. René Brecht, VP Process Science & Manufacturing
Dr. René Brecht, VP Process Science & Manufacturing

Dr René Brecht joined ProBioGen in 2002 and is Vice President of Process Science and Manufacturing. René Brecht is responsible for process development for recombinant proteins and antibodies as well as for fusion proteins, up to GMP manufacturing of clinical materials. Prior to joining ProBioGen, he held a position as Research Scientist at the University of Leipzig, where he was responsible for pre-clinical and GMP process development of monoclonal antibodies and antibody fragments for therapeutic and diagnostic purposes. René Brecht received his doctorate in Pharmaceutical Chemistry from the University of Marburg on natural occurring anticancer compounds.

Andrea Hauptmann, VP Finance & Administration
Andrea Hauptmann, VP Finance & Administration

Vice President Finance & Administration at ProBioGen since 2015. Andrea Hauptmann has been responsible for financial reporting, controlling, funding and cash management, risk management, human resources and administration since 2011. Before joining ProBioGen in 2009, she held a number of key financial management positions in the service and real estate sector. Andrea Hauptmann holds a diploma in economics. She was granted power of attorney in 2009.

Partners

The remarkable scientific progress in the last two decades has given rise to the development of new technologies at an unprecedented pace. We continuously screen the market and leverage our global network to identify and evaluate potential partners. Our partnerships are collaborative and target specific results, with a strong focus on value for our end customers.

Thermo Fisher Scientific

We engineered the Freedom™ CHO-S™ Kit platform, which enables cost-and-time-efficient stable cell line development for research and commercial purposes, in close collaboration with Thermo Fisher Scientific. The kit is available via Thermo Fisher Scientific.

Boehringer Ingelheim

Boehringer Ingelheim has a non-exclusive license for ProBioGen’s proprietary GlymaxX® ADCC enhancement technology (Antibody-Dependent Cell-Mediated Cytotoxicity). Under this license, Boehringer Ingelheim applies GlymaxX for third parties from its global contract manufacturing platform as well as to its own development candidates, to produce antibodies with enhanced ADCC potency.

References

Our customer range is extensive; some of our key customers and selected references are:

References

Please feel free to contact us regarding our references. We are more than happy to connect you with relevant clients on an individual basis.

For further information please contact us at

Quality Management

The high quality of ProBioGen’s products relies on the synergetic improvement of each individual process step. Our quality management system is based on standard DIN EN ISO 9001:2008 and specifically tailored to serve our client's individual requirements. ProBioGen holds a manufacturing authorization for GMP compliant manufacturing and batch release of biotechnological drug substances.

Learn more

Your Objectives

Are you looking to enhance your program or are you just curious about our company, services, and technologies? Connect with our team and we will get back to you shortly.

 

Note:  The right to object concerns the processing of data based on our legitimate interest (Art. 6 lit. f GDPR) as well as the processing for direct marketing. You can revoke your consent at any time for the future by e-mail to cmo@probiogen.de.

Detailed information on the handling of user data can be found in our Data Protection Statement.

*Required